卡迪夫肿瘤学第二季度每股收益$（0.21）错过$（0.20）估计，销售额121，00，00，00，00，00，00，000美元估计

Cardiff Oncology (NASDAQ: CRDF) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 5 percent. This is a 19.23 percent increase over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $121.00 thousand which beat the analyst consensus estimate of $92.86 thousand by 30.31 percent. This is a 25.77 percent decrease over sales of $163.00 thousand the same period last year.